Anastrozole/levonorgestrel intravaginal ring - Bayer HealthCare

Drug Profile

Anastrozole/levonorgestrel intravaginal ring - Bayer HealthCare

Alternative Names: BAY 98-7196; Bay98-7196

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Class Nitriles; Norpregnanes; Oral contraceptives; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pregnancy
  • Phase II Endometriosis

Most Recent Events

  • 01 Oct 2016 Bayer completes a phase-II clinical trial in Endometriosis in Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, Japan Netherlands, Norway, Poland, Spain, Switzerland and USA (NCT02203331)
  • 01 Jul 2016 Bayer completes a phase I trial for Endometriosis in Germany (NCT02545452)
  • 01 Jul 2016 Bayer completes a phase III trial for Contraception in USA and Japan (NCT02403401)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top